TY - JOUR
T1 - Biologic markers in axillary node-negative breast cancer
T2 - Differential expression in invasive ductal carcinoma versus invasive lobular carcinoma
AU - Gonzalez-Angulo, Ana Maria
AU - Sahin, Aysegul
AU - Krishnamurthy, Savitry
AU - Yang, Ying
AU - Kau, Shu Wan
AU - Hortobagyi, Gabriel N.
AU - Cristofanilli, Massimo
N1 - Funding Information:
This work was supported by the Nellie B. Connally Breast Cancer Research Fund, the Susan G. Komen Breast Cancer fellowship, and the Texas Federation of Business and Professional Women. This work was presented in part at the 95th American Association of Cancer Research Annual Meeting in Orlando, FL, March 27-31, 2004.
PY - 2006/12
Y1 - 2006/12
N2 - Purpose: The objective of this study was to compare the differential expression of established histopathologic and biologic markers of proliferation, apoptosis, and angiogenesis in invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) in a group of axillary node-negative breast cancers. Patients and Methods: Two hundred twenty patients with axillary node-negative ILC and IDC who underwent surgery at the University of Texas M. D. Anderson Cancer Center between 1978 and 1995 had tissue available for analysis. Of these, 206 (94%) had IDC and 14 (6%) had ILC. Estrogen receptors, progesterone receptors, tumor and stromal expression of vascular endothelial growth factor receptor 2, CD44, laminin-5, E-cadherin, and topoisomerase-2 were evaluated by immunohistochemical analysis. HER2/neu and α6β4 integrin were evaluated by in situ hybridization. The Fisher exact test was used to calculate significant differences between ILC and IDC. Median age was 59 years. Results: Invasive lobular carcinoma was more likely to occur in patients aged > 50 years. Invasive lobular carcinoma tended to be > 2 cm (50% vs. 39%), have a nuclear grade of 1/2 (100% vs. 72%), be estrogen receptor positive (93% vs. 70%), HER2/neu negative (92% vs. 68%), have high CD44 expression (31% vs. 16%), low stromal vascular endothelial growth factor receptor 2 expression (36% vs. 47%), no E-cadherin expression (0 vs. 90%), and low laminin-5 expression (15% vs. 25%), compared with IDC. Conclusion: Invasive lobular carcinoma and IDC might be distinct histologic types of breast cancer with different expression of biologic markers. These differences, not all being statistically significant in this small study, might generate hypotheses to develop tailored options for future systemic therapy.
AB - Purpose: The objective of this study was to compare the differential expression of established histopathologic and biologic markers of proliferation, apoptosis, and angiogenesis in invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) in a group of axillary node-negative breast cancers. Patients and Methods: Two hundred twenty patients with axillary node-negative ILC and IDC who underwent surgery at the University of Texas M. D. Anderson Cancer Center between 1978 and 1995 had tissue available for analysis. Of these, 206 (94%) had IDC and 14 (6%) had ILC. Estrogen receptors, progesterone receptors, tumor and stromal expression of vascular endothelial growth factor receptor 2, CD44, laminin-5, E-cadherin, and topoisomerase-2 were evaluated by immunohistochemical analysis. HER2/neu and α6β4 integrin were evaluated by in situ hybridization. The Fisher exact test was used to calculate significant differences between ILC and IDC. Median age was 59 years. Results: Invasive lobular carcinoma was more likely to occur in patients aged > 50 years. Invasive lobular carcinoma tended to be > 2 cm (50% vs. 39%), have a nuclear grade of 1/2 (100% vs. 72%), be estrogen receptor positive (93% vs. 70%), HER2/neu negative (92% vs. 68%), have high CD44 expression (31% vs. 16%), low stromal vascular endothelial growth factor receptor 2 expression (36% vs. 47%), no E-cadherin expression (0 vs. 90%), and low laminin-5 expression (15% vs. 25%), compared with IDC. Conclusion: Invasive lobular carcinoma and IDC might be distinct histologic types of breast cancer with different expression of biologic markers. These differences, not all being statistically significant in this small study, might generate hypotheses to develop tailored options for future systemic therapy.
KW - CD44
KW - E-cadherin
UR - http://www.scopus.com/inward/record.url?scp=33846503936&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846503936&partnerID=8YFLogxK
U2 - 10.3816/CBC.2006.n.056
DO - 10.3816/CBC.2006.n.056
M3 - Article
C2 - 17239264
AN - SCOPUS:33846503936
SN - 1526-8209
VL - 7
SP - 396
EP - 400
JO - Clinical breast cancer
JF - Clinical breast cancer
IS - 5
ER -